Search results for AstraZeneca - Clinical Trials Registry - ICH GCP

Example: Heart Attack

Clinical Trials Sponsored by AstraZeneca

Total 4002 results

NCT05184062

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Conditions: Coronavirus Disease 2019 (COVID-19)
NCT04214288

Active, not recruiting

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
NCT04039113

Active, not recruiting

Tezepelumab COPD Exacerbation Study

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
NCT03003962

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Conditions: Non Small Cell Lung Carcinoma NSCLC
NCT02184195

Active, not recruiting

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Conditions: Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
NCT05705869

Recruiting

Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure

Conditions: Heart Failure, Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes, Cardiovascular Diseases
NCT05517226

Recruiting

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Conditions: Hepatic Impairment
NCT05047172

Recruiting

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Conditions: Intracranial Arteriosclerosis, Stroke
NCT04598919

Recruiting

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
NCT04353973

Recruiting

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

Conditions: Cancer
NCT02542293

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).

Conditions: Non Small Cell Lung Carcinoma NSCLC
NCT02537418

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Conditions: Solid Malignancies
NCT02272790

Active, not recruiting

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
NCT02125461

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Conditions: Non-Small Cell Lung Cancer
NCT03907137

Completed

Real World Study With Benralizumab in Severe Asthma in Switzerland

Conditions: Severe Eosinophilic Asthma
NCT03290287

Completed

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

Conditions: Pulmonary Disease, Chronic Obstructive
NCT05583227

Recruiting

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Conditions: Eosinophilic Esophagitis
NCT05469919

Recruiting

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Conditions: Advanced Solid Malignancies
NCT05465213

Recruiting

Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)

Conditions: Heart Failure
NCT05251259

Recruiting

Study to Assess the Efficacy and Safety of AZD5718 in Moderate-to-Severe Uncontrolled Asthma

Conditions: Asthma
NCT05219162

Recruiting

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Conditions: Advanced NSCLC
NCT05188144

Recruiting

Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.

Conditions: Heart Failure
NCT04336943

Recruiting

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
NCT03739931

Recruiting

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Conditions: Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
NCT03212287

Recruiting

Brilinta Clinical Experience Investigation

Conditions: Acute Coronary Syndrome, Old Myocardial Infarction